<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="251">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00445965</url>
  </required_header>
  <id_info>
    <org_study_id>05-122</org_study_id>
    <secondary_id>MSKCC-05122</secondary_id>
    <nct_id>NCT00445965</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer</brief_title>
  <official_title>Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8,
      can find tumor cells and carry tumor-killing substances to them without harming normal
      cells. This may be an effective treatment for central nervous system cancer or
      leptomeningeal metastases.

      PURPOSE: This phase II trial is studying the side effects and how well iodine I 131
      monoclonal antibody 3F8 works in treating patients with central nervous system cancer or
      leptomeningeal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine if intrathecal iodine I 131 monoclonal antibody 3F8 activity in patients with
           GD2-expressing central nervous system or leptomeningeal neoplasms is sufficiently
           promising (i.e., 6-month overall survival rate ≥ 25%) to warrant further study.

        -  Determine the response rate in patients treated with this drug.

        -  Determine the cumulative toxicities of this drug in these patients.

        -  Describe the effects of human-antimouse antibody on cerebrospinal fluid and serum
           pharmacokinetics in patients treated with this drug.

      OUTLINE: This is an open-label study.

      Patients receive intrathecal iodine I 131 monoclonal antibody 3F8 for dosimetry. Beginning
      approximately 1 week later, patients receive intrathecal iodine I 131 monoclonal antibody
      3F8 on day 1. Treatment intrathecal iodine I 131 monoclonal antibody 3F8 repeats weekly for
      up to 4 courses in the absence of disease progression or unacceptable toxicity.

      Blood and cerebrospinal fluid samples are collected prior to and after administration of
      each course of study drug. Samples are analyzed to assess the intrathecal and blood
      pharmacokinetics of iodine I 131 monoclonal antibody 3F8 and serum human antimouse
      antibodies. Samples are also analyzed in tumor genetic studies.

      After completion of study treatment, patients are followed periodically for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Six-month overall survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A &quot;response&quot; is defined as a patient being alive six months after their first treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative toxicities</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicities will be assessed via the NCI toxicity criteria (CTC 3.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Intraocular Melanoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <arm_group>
    <arm_group_label>131I-3F8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody 3F8</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>131I-3F8</intervention_name>
    <description>Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.</description>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed GD2-expressing malignancy, including the following:

               -  Medulloblastoma or primitive neuroectodermal tumor of the CNS

               -  High-grade astrocytoma

               -  Malignant glioma

               -  Neuroblastoma

               -  Retinoblastoma

               -  Ependymoma

               -  Rhabdoid tumors

               -  Sarcomas

               -  Melanoma

               -  Small cell lung carcinoma

               -  Desmoplastic small round cell tumor

               -  Other tumor types with GD2 expression confirmed by immunohistochemical staining
                  and assessed by the Memorial Sloan-Kettering Department of Pathology using prior
                  frozen tissue, bone marrow, or cerebrospinal fluid cytology

          -  Must meet 1 of the following criteria:

               -  Refractory to conventional therapies

               -  Disease for which no conventional therapy exists

               -  Recurrent brain tumors with a predilection for leptomeningeal dissemination
                  (e.g., medulloblastoma, supratentorial primitive neuroectodermal tumor, rhabdoid
                  tumor)

          -  Patients with active malignancy outside the central nervous system are eligible

               -  No obstructive or symptomatic communicating hydrocephalus

        PATIENT CHARACTERISTICS:

          -  Absolute neutrophil count &gt; 1,000/mm³

          -  Platelet count &gt; 50,000/mm³

          -  No uncontrolled life-threatening infection

          -  No rapidly progressing or deteriorating neurologic examination

          -  No severe major organ toxicity (i.e., renal, cardiac, hepatic, pulmonary, and
             gastrointestinal system toxicity ≤ grade 2)

          -  Stable neurological deficits (due to brain tumor) allowed

          -  No hearing loss &gt; 3

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  No cranial or spinal irradiation within the past 3 weeks

          -  No prior craniospinal radiation &gt; 45 Gy or focal brain radiation &gt; 72 Gy

          -  No systemic chemotherapy within the past 3 weeks (corticosteroids allowed)

          -  Programmable shunt allowed
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Kramer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Kramer, MD</last_name>
    <phone>212-639-6410</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nai-Kong Cheung, MD, PhD</last_name>
    <phone>646-888-2313</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Kramer, MD</last_name>
      <phone>212-639-6410</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials/MSKCC-05122</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>March 7, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>untreated childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>childhood mixed glioma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>untreated childhood visual pathway glioma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>extraocular retinoblastoma</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult desmoplastic small round cell tumor</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood desmoplastic small round cell tumor</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>intraocular retinoblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>metastatic intraocular melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>untreated childhood pineoblastoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <keyword>recurrent childhood anaplastic astrocytoma</keyword>
  <keyword>untreated childhood anaplastic astrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
  <keyword>untreated childhood anaplastic oligoastrocytoma</keyword>
  <keyword>untreated childhood anaplastic oligodendroglioma</keyword>
  <keyword>recurrent childhood giant cell glioblastoma</keyword>
  <keyword>recurrent childhood glioblastoma</keyword>
  <keyword>untreated childhood giant cell glioblastoma</keyword>
  <keyword>untreated childhood glioblastoma</keyword>
  <keyword>recurrent childhood gliosarcoma</keyword>
  <keyword>untreated childhood gliosarcoma</keyword>
  <keyword>recurrent childhood gliomatosis cerebri</keyword>
  <keyword>untreated childhood gliomatosis cerebri</keyword>
  <keyword>childhood high-grade cerebellar astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Duodenal Neoplasms</mesh_term>
    <mesh_term>Ileal Neoplasms</mesh_term>
    <mesh_term>Jejunal Neoplasms</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Meningeal Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
